<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00304551</url>
  </required_header>
  <id_info>
    <org_study_id>JV19595</org_study_id>
    <nct_id>NCT00304551</nct_id>
  </id_info>
  <brief_title>A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)</brief_title>
  <official_title>A Phase II/III Study of Peginterferon Alfa-2a in Combination With Ribavirin for the Treatment of CHC With Compensated LC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chugai Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated the clinical response of the efficacy and safety of the combination
      therapy of peginterferon alfa-2a and ribavirin, compared with an antiviral treatment-free
      group in CHC patients with compensated LC.

      Additionally, this study evaluated the dosage reactivity and the pharmacokinetic
      characteristics of the combination therapy of peginterferon alfa-2a and ribavirin in CHC
      patients with compensated LC.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virological response, defined as undetectable hepatitis C virus (HCV)-RNA (&lt; 50 IU per milliliter [IU/mL])</measure>
    <time_frame>week 24 from the end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical response (normalization of serum alanine aminotransferase activity)</measure>
    <time_frame>at the end of treatment and week 24 form the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological response (HCV-RNA &lt; 50 IU per milliliter)</measure>
    <time_frame>at the end of treatment and week 24 form the end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa-2a 180μg</intervention_name>
    <description>180μg（s.c.）/week for 48 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa-2a 90μg</intervention_name>
    <description>90μg(s.c.)/week for 48 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin</intervention_name>
    <description>600, 800, or 1,000 mg X 2(p.o.)/day</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 20 to 75 years-old with quantifiable serum HCV-RNA (≥ 500 IU/mL),
             elevated serum alanine aminotransferase activity (≥ 45 IU per liter) within sixty days
             of screening, and proven CHC with compensated LC (Child-Pugh A) on liver biopsy.

        Exclusion Criteria:

          -  Patients with neutropenia (fewer than 1,500 neutrophils per cubic millimeter)

          -  Thrombocytopenia (fewer than 75,000 platelets per cubic millimeter)

          -  Anemia (less than 12 g hemoglobin per deciliter )

          -  Hepatitis B co-infection; decompensated liver disease.

          -  Organ transplant

          -  Creatinine clearance less than 50 milliliters per minute

          -  Poorly controlled psychiatric disease

          -  Poorly controlled diabetes

          -  Malignant neoplastic disease

          -  Severe cardiac or chronic pulmonary disease

          -  Immunologically mediated disease

          -  Retinopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takehiko Aoshima</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Research Department 4, Chugai Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chugoku</name>
      <address>
        <city>Chugoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido Region</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanto Region</name>
      <address>
        <city>Kanto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinki Region</name>
      <address>
        <city>Kinki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyusyu Region</name>
      <address>
        <city>Kyusyu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shikoku Region</name>
      <address>
        <city>Shikoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku Region</name>
      <address>
        <city>Tohoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokai Region</name>
      <address>
        <city>Tokai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2006</study_first_submitted>
  <study_first_submitted_qc>March 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2006</study_first_posted>
  <last_update_submitted>June 1, 2010</last_update_submitted>
  <last_update_submitted_qc>June 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chugai Pharmaceutical</name_title>
    <organization>Chugai Pharmaceutical</organization>
  </responsible_party>
  <keyword>CHC with compensated LC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

